Evolocumab (Repatha)
Evolocumab risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Repatha.
Evolocumab (brand names: Repatha) is classified as Minimal risk by AllMeds. It is a S4 medication under the TGA in Australia. PCSK9 inhibitor injection with no impairment or safety concerns for work activities.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Minimal (0 points)
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
PCSK9 inhibitor injection with no impairment or safety concerns for work activities.
Regulatory and Compliance Guidance
When Evolocumab appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Need to assess this medication across your caseload?
Run a full risk assessment including Evolocumab interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.